 |
 |
 |
 |
 |
 |
 |
||||
|
||||||||||
 Construction, Characterization and PathologyPolypeptide Growth Factors and Prostate CancerAndrogen Axis and Prostate CancerImmunotherapyPre-Clinical TrialsReviews |
1. Kwon, E.D., Hurwitz, A.A., Foster, B.A., Madias, C., Feldhaus, A.L., Greenberg, N.M., Burg, M.B and Allison, J.P. 1997. Modulation of T cell costimulation and inhibition for immunotherapy of prostate cancer. Proc Natl Acad Sci (USA) 94:8099-8103. [PDF] 2. Kwon, E.D., Foster, B.A., Hurwitz, A.A., Madias, C., Allison, J.P., Greenberg, N.M. and Burg, M.B. 1999. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. PNAS (USA) 96:15074-15079. [PDF] 3. Granziero L, Krajewski S, Farness P, Yuan L, Courtney MK, Jackson MR, Peterson PA, Vitiello A. 1999. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur J Immunol Apr;29(4):1127-38 [PDF] Hurwitz, A.A., Foster, B.A. Kwon, E,D., Truong, T., Choi, E.M., Greenberg, N.M., Burg, M., and Alison, J.P. 2000. Combination immunotherapy of primary prostate cancer in a transgenic model using CTLA-4 blockade. Cancer Research 60:2444-2448. [PDF] 4. Allison, J.P., Hurwitz, A.A., Van Elsa, A., Kwon, E., Sullivan, T., Foster, B and Greenberg, N. 2000. CTLA-4 blockade in tumor immunotherapy. In: Principle and Practice of the Biologic Therapy of Cancer 3rd Ed. (S. Rosenberg ed., Lippincott Williams & Wilkins,) pp-890-895. 5. Hill, R.E., De Avila, D.M., Bertrand, K.P., Greenberg, N.M. and Reeves, J. 2003. Immunization Against Leutinizing Hormone Releasing Hormone Fusion Proteins Does Not Decrease Prostate Cancer In The Transgenic Adenocarcinoma Mouse Prostate Model. Exp. Biol. Med. 228: 818-822.[PDF] |
